Generics· August 18, 2026 · 14 min read
Generic Wakix Approved but Cannot Launch Until 2030: The Orange Book Fence
By Ran Chen#Orange Book#Generics#Generic Entry
Topic
Orange Book
Patent/exclusivity records, therapeutic-equivalence codes, reference-listed drugs, and ANDA planning.
Pricing & Access· August 16, 2026 · 18 min read
Hepatitis C Treatment Access in 2026: Generic Economics, PA, and Sobriety
Specialty· August 15, 2026 · 23 min read
Prostate Cancer Treatment Access Landscape: Xtandi Patent Wall & Generics
By Ran Chen#Oncology#Generic Entry#Orange Book
Pricing & Access· August 8, 2026 · 14 min read
Novo Nordisk portfolio dossier (Q2 2026): Wegovy, CagriSema & obesity pipeline
By Ran Chen#Novo Nordisk#Semaglutide#Wegovy
Deals· August 3, 2026 · 15 min read
Neurocrine's $2.9 Billion Soleno Acquisition: Vykat XR and the Prader-Willi Franchise
By Ran Chen#M&A#Rare Disease#Orange Book
Deals· August 2, 2026 · 25 min read
Angelini Pharma's $4.1B Catalyst Acquisition: Rare Disease Deal Anatomy
By Ran Chen#M&A#Rare Disease#Orange Book
Pricing & Access· August 1, 2026 · 23 min read
Parkinson's Disease Treatment Access: From $0.08 Levodopa to Tavapadon
Specialty· July 30, 2026 · 20 min read
Non-Stimulant ADHD Access Landscape (2026): Simtriyo NDSRI & Generic Economics
Pricing & Access· July 16, 2026 · 23 min read
Atopic dermatitis systemic access: Dupixent, JAK inhibitors, and biologics
Generics· July 15, 2026 · 29 min read
2026–2027 Generic Launch Scorecard: Which Patent Cliffs Are Worth Filing
By Ran Chen#Orange Book#Generic Entry#ANDA Approval